New combo therapy aims to tame tough lung cancer
NCT ID NCT07465757
First seen Mar 23, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This study tests how well people with small cell lung cancer tolerate a new drug, alisertib, when added to standard chemotherapy (paclitaxel). About 50 adults who have already tried at least one prior treatment will take alisertib pills twice daily for a week, plus IV paclitaxel twice per cycle. The main goal is to track side effects and find the safest dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER, SCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.